Jeffrey N. Fredman
110 IP cases indexed. Covers patent matters.
Cases Presided Over
110 cases indexed | Page 3 of 4
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s patent on enablement and obviousness grounds in a PTAB decision. The Board found that the patent documents supported a broad definition of modified PH20 polypeptides, while noting the petitioner had established a likelihood of prevailing on enablement but failed to prove obviousness.
CSPC Pharmaceutical Group Limited et al. v.Ipsen Biopharm Ltd. et al.
The PTAB institution decision in this oncology IPR upheld the patent claims against numerous prior art references related to FOLFIRINOX and nanoliposomal irinotecan. The Board adopted a specific claim construction defining 'treatment' as requiring more than a de minimis therapeutic benefit for the patient.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
The PTAB instituted the PGR petition challenging Halozyme's patent covering modified PH20 polypeptides. The Board found that the claims were not sufficiently supported by the specification regarding enablement and obviousness, despite Petitioner's arguments about the genus size.
ITM Isotope Technologies Munich SE v.The Johns Hopkins University et al.
ITM Isotope Technologies and Johns Hopkins settled their dispute over U.S. Patent 11,938,201, leading the PTAB to grant a joint motion to terminate the post‑grant review.
ITM Isotope Technologies Munich SE v.The Johns Hopkins University et al.
ITM Isotope Technologies Munich SE challenged The Johns Hopkins University's claims regarding FAP-α targeting moieties based on obviousness and patentability issues (103/112). The Board instituted the PGR, finding that the claims face significant challenges related to enablement and indefiniteness.
Ajinomoto Co., Inc. v.AbTis Co., Ltd.
Ajinomoto Co., Inc. successfully convinced the PTAB to institute an IPR against AbTis Co., Ltd.'s patent (11896675) covering Antibody-Drug Conjugates (ADCs). The Board found sufficient evidence for institution on multiple grounds of anticipation and obviousness regarding claim 11.
Therabody, Inc. v.Hyperice IP Subco, LLC et al.
Therabody successfully challenged Hyperice's patent claims in a PTAB proceeding focused on massaging devices. The Board found likelihood of unpatentability based on obviousness and statutory deficiencies, particularly regarding the combination of prior art references.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB has instituted an inter partes review of Inari Medical’s 11,865,291 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. All challenged claims (1‑8, 12‑19) are now subject to trial.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,012 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on all nine challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable. Petitioner Imperative Care proved anticipation and obviousness over Schaffer, Hartley, Eller and Garrison, with the Board emphasizing that the claimed filament must be flexible.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after Imperative Care showed a reasonable likelihood of success. All challenged claims (1‑7, 9‑10, 15‑18, 20‑24) are now under review.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,011 B2 hemostasis valve patent after finding Imperative Care’s likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB denied Imperative Care’s petition to institute an IPR against Inari Medical’s U.S. Patent 11,744,691, finding no reasonable likelihood of success. The Board concluded the cited prior art did not disclose the required negative‑pressure pump configuration.
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care challenges Inari Medical's hemostasis valve patent (11554005) on obviousness grounds. The PTAB instituted the IPR, requiring further review of claims 1-15 based on prior art combinations.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s patent on modified PH20 polypeptides in a PGR proceeding. The Board found likelihood of prevailing based on arguments regarding the genus's scope and potential lack of enablement/obviousness.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB denied the institution of an IPR challenge against Inari Medical's patent (11744691) covering emboli treatment systems. The Board found that the petitioner, Imperative Care, Inc., failed to demonstrate a reasonable likelihood of prevailing on its grounds of anticipation and obviousness.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully petitioned the PTAB against Halozyme, Inc.'s '298 patent covering modified PH20 polypeptides. The Board granted institution despite challenges based on Written Description and Enablement, allowing the dispute to proceed to trial.
Garmin International, Inc. v.Cardiacsense LTD
Garmin and Cardiacsense settled their IPR dispute over patent 7,980,998, leading the PTAB to terminate the proceeding without a final decision.
Garmin International, Inc. v.Cardiacsense LTD
Garmin International successfully navigated the initial stages of its IPR challenge against Cardiacsense LTD's '998 patent, establishing a reasonable likelihood of prevailing on several grounds. The Board found that certain claims were not entitled to an earlier effective filing date due to insufficient written description support for a compass feature in prior applications.
Azurity Pharmaceuticals, Inc. v.EXELIXIS, INC.
Azurity Pharmaceuticals failed to convince the PTAB that EXELIXIS's drug formulation patent was unpatentable, resulting in a denial of institution for IPR2025-00210. The Board rejected anticipation arguments based on prior art family relationships and dismissed obviousness claims regarding impurity control.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s claims regarding modified PH20 polypeptides in a PTAB decision. The Board instituted trial based on enablement and written description grounds, finding that the broad genus of claimed molecules required undue experimentation to identify active variants.
Therabody, Inc. v.Hyperice IP Subco, LLC et al.
Therabody, Inc. successfully convinced the PTAB to institute proceedings against Hyperice IP Subco, LLC regarding a medical device patent (11857482). The Board found prima facie evidence of obviousness and indefiniteness across multiple claims based on prior art combinations.
Therabody, Inc. v.Hyperice IP Subco, LLC et al.
Therabody challenged Hyperice's patent on percussive massagers based on indefiniteness and obviousness, but the PTAB upheld the claims. The Board found that key terms like 'substantially cylindrical' were supported by functional limitations in the specification.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom successfully petitioned to institute an IPR against Abbott Diabetes Care Inc.'s glucose monitoring patent (11298056). The Board found a reasonable likelihood of prevailing on grounds of obviousness (103) for claims 13 and 29.
Simpson Strong-Tie Company Inc. et al. v.Columbia Insurance Company et al.
Simpson Strong‑Tie and Columbia Insurance reached a confidential settlement, prompting the PTAB to terminate the post‑grant review of patent 11,920,339. The Board granted the joint motion to keep the settlement confidential and end the proceeding.
Simpson Strong-Tie Company Inc. et al. v.Columbia Insurance Company et al.
The PTAB decided to institute PGR proceedings, finding that the Petitioner successfully overcame arguments of Examiner error regarding prior art combinations and claim construction issues. The dispute centers on fire-resistant wall assemblies and truss hangers, with the Board issuing preliminary determinations on key terms like 'planar extension plate' and 'bounding.'
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 embolism‑treatment patent after finding Imperative Care likely to prevail on at least one claim, primarily on obviousness grounds involving hemostasis valve features.
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care has successfully instituted an inter partes review of Inari Medical’s 11,697,011 hemostasis valve patent, asserting anticipation and obviousness over three prior‑art references. The Board found a reasonable likelihood of unpatentability on at least one claim and ordered the trial to proceed.
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care challenges Inari Medical's hemostasis valve patents under grounds of anticipation and obviousness. The Board construed the key term 'filament' to require flexibility, which influenced its initial assessment of the claims. Institution was granted, setting the stage for a full trial on infringement and validity.
Imperative Care, Inc. v.Inari Medical, Inc.
The Board found that the claims were obvious over prior art references by combining known features to achieve a predictable result. Despite initial disputes over claim construction, the Petitioner failed to provide sufficient motivation for combining specific prior art elements.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.